NOVIGO Pharma Inc.

Our company was founded in 2021 as a venture originating from Kyushu University. Leveraging our proprietary nanoparticle technology, we are developing transdermal drug delivery technology, which enables simple and effective drug absorption through the skin, reducing the burden on patients, as well as intracellular delivery technology that facilitates drug delivery into cells and extracellular vesicles. Our goal is to establish a platform for drug delivery systems (DDS).

Series A and A2 Funding Rounds Completed
With support from NEDO projects, we have successfully conducted two rounds of funding, in November 2021 and April 2024.

Research Phase Overview
The research targeted in this recruitment is at the formulation development stage, focusing on collaborative development with companies and academia as we approach preclinical trials. For our earliest projects, we plan to initiate preclinical trials in late 2025.